Clinical Trial Search

Primary: Recurrence-free Survival (RFS) — 52.37; 24.08 Months — p=0.0003

Primary: Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic…

Primary: Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity During the 12-week Period After the First Dose of…

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 265; 300; 97; 21 participants

Primary: Induction Phase: Percentage of Participants With Remission at Week 14, as Determined by the Mayo Clinic Score (MCS) — 6.3; 18.5 Percentage of Participants — p=0.0033

Primary: Number of Participants With Adverse Events (AEs) in Retrospective Observation Period — 23; 4; 23; 4 Participants

Primary: Correct Localization Rate (CLR) — 85.6; 87.0; 84.8 percentage of participants

Primary: Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale — 163; 2…

Primary: Proportion of Patients With Clinical Remission at Week 12 — 0.00; 0.042; 0.087; 0.071 Proportion of Participants

Primary: Annualized Confirmed Relapse Rate — 0.202; 0.290 relapses per year — p=0.0003

Primary: Evaluation of Decayed, Missing, and Filled Tooth Surfaces (Dmfs) at Baseline — 19.9; 22.8 dmfs

Primary: Overall Survival — 11.43; 11.73 Months

Primary: Change in Ambulatory Blood Pressure Monitoring (ABPM)-Measured Average 24-hour Systolic Blood Pressure (SBP) — 3.8 mmHg

Primary: Intraocular Pressure (IOP) at Week 12 — 20.6; 20.8 mmHg

Primary: Responder Rate — 178; 167; 175; 0 Participants